2Firsts
March 17, 2026
Glas Inc. has confirmed to 2Firsts that the device granted marketing authorization by the U.S. Food and Drug Administration (FDA) on March 12 (U.S. Eastern Time) is its Glas G2 platform and that it incorporates age-gating technology, meaning that, based on currently public information, the FDA has authorized the first electronic nicotine delivery system (ENDS) product confirmed to include such a feature.
In a message to 2Firsts, Kevin Higgins, chief operating and financial officer of Glas Inc., said the product that received the marketing granted order “is the Glas G2 device” previously discussed with 2Firsts and that it “does incorporate advanced, proven age-gating and counterfeit-detection technology.”
The confirmation validates 2Firsts’ earlier reporting on the platform behind the authorization.
On March 13, 2Firsts reported that the FDA had granted marketing authorization to a Glas device and a Blonde Tobacco pod, bringing the number of FDA-authorized ENDS products to 41. In a follow-up report published on March 14, 2Firsts reported that the FDA had updated the authorized product name to “Glas G2,”and, based on that change, inferred that the device receiving the marketing granted order likely corresponded to the Glas G2 platform previously described by the company as incorporating age-verification technology.
2Firsts will continue to monitor developments in the U.S. PMTA process.
Cover image generated by AI.
Further reading:
